10-Q: Recursion Pharmaceuticals Q1 2026 Financial Update

Recursion Pharmaceuticals reports a decrease in revenue and operating costs for Q1 2026, with a net loss of $117.5 million, while advancing its drug discovery platform and pipeline.

Summary

• Recursion Pharmaceuticals reported total revenue of $6.47 million for the three months ended March 31, 2026, a decrease of 56% compared to $14.75 million in the same period of 2025.
• Total operating costs and expenses decreased by 35% to $134.98 million from $206.11 million in the prior year's quarter.
• The company reported a net loss of $117.5 million for the quarter, an improvement from a net loss of $202.49 million in Q1 2025.
• Cash, cash equivalents, and restricted cash stood at $665.2 million as of March 31, 2026, which the company believes is sufficient to fund operations for at least the next twelve months.
• Key pipeline programs like REC-1245 and REC-4881 are advancing, with positive preliminary data and ongoing clinical studies.
• The company continues to invest in its AI-native drug discovery platform, Recursion OS, with advancements in transcriptomics models like TxFM.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While pipeline progress and platform advancements are positive, the significant revenue decline and continued substantial net losses present considerable financial challenges.

Positives

• Net loss improved significantly to $117.5 million from $202.5 million in the prior year's quarter.
• Operating costs and expenses decreased by 35% to $134.98 million, indicating improved operational efficiency.
• REC-1245 (RBM39 degrader) showed favorable preliminary safety and PK data in Phase 1/2 study, with no dose-limiting toxicities observed.
• REC-4881 (MEK1/2 inhibitor) demonstrated positive Phase 2 proof-of-concept data with a significant reduction in polyp burden for FAP patients.
• REC-4539 (LSD1 inhibitor) has dosed its first patient in the ENLYGHT Phase 1 study.
• The company's AI-native platform, Recursion OS, continues to drive innovation, with advancements in transcriptomics models like TxFM, which outperforms leading foundation models.
• Cash reserves remain substantial at $665.2 million, providing at least 12 months of operational runway.

Negatives

• Total revenue decreased by 56% to $6.47 million, primarily due to a decrease in revenue recognized from the Roche collaboration.
• The company continues to incur substantial operating losses, with an accumulated deficit of $2.2 billion as of March 31, 2026.
• The company anticipates needing to raise additional financing in the future to fund operations and potential commercialization.
• Material weaknesses in internal control over financial reporting persist, although remediation efforts are underway.
• Stock-based compensation expense remains significant, totaling $21.995 million for the quarter.

Risks

• The company expects to incur substantial operating losses in future periods and requires additional capital to advance its drug candidates.
• There is uncertainty regarding clinical trial outcomes and the ability to secure additional funding.
• The company may not be able to access additional funds when needed, which could force it to delay, scale back, or abandon development programs.
• The company is subject to risks associated with the development of novel drug candidates, including the uncertainty of regulatory approvals.
• Intellectual property disputes and the ability to defend against claims of infringement are potential risks.
• The company relies on third parties for clinical trials and manufacturing, introducing potential risks.
• The company faces competition in a highly competitive market.
• The company has a history of operating losses and negative operating cash flows.

Future Outlook

Recursion expects to continue incurring substantial operating losses and requires additional capital. The company believes its current cash and cash equivalents are sufficient to fund operations for at least the next twelve months. Updates on clinical development, including regulatory engagement for REC-4881 and data from other pipeline programs, are expected in the second half of 2026 and first half of 2027. The company anticipates needing to raise additional financing in the future.

Management Comments

• The company's AI-native platform, Recursion OS, is designed to translate complex science into medicines faster, better, and at scale.
• REC-1245 advanced from biological discovery to development candidate in 18 months, demonstrating the platform's ability to identify novel targets and design differentiated molecules.
• REC-4881 Phase 2 data showed a median 43% reduction in polyp burden, supporting a differentiated and durable profile in FAP.
• TxFM, a transcriptomics foundation model, outperforms leading foundation models and drives operational efficiency.
• The company believes its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditures for at least the next twelve months.

Industry Context

StockSavvy.ai notes that Recursion Pharmaceuticals' Q1 2026 results reflect the ongoing challenges and significant investment required in the early-stage biotechnology sector, particularly for companies leveraging AI in drug discovery. The decrease in revenue is attributed to the completion of project phases in collaborations, a common occurrence as projects mature. The company's focus on platform advancement and pipeline progression, despite substantial net losses, aligns with industry trends where long-term value is driven by successful drug development and platform innovation.

Comparison to Industry Standards

• REC-1245 advanced from discovery to development candidate in 18 months, which is more than twice as fast as the industry average for similar programs.
• The company's net loss of $117.5 million for the quarter, while substantial, represents an improvement from the previous year, indicating efforts to manage cash burn.
• The revenue decline of 56% is largely due to the cyclical nature of milestone payments in large R&D collaborations, a common pattern for companies at Recursion's stage.
• TxFM, a transcriptomics foundation model, demonstrated superior performance compared to 16 leading foundation models and baselines, even those trained on significantly larger datasets, highlighting a potential competitive advantage in AI-driven biology.

Corporate Governance

Legal Proceedings

• Industry Office SLC, LLC v. Recursion Pharmaceuticals, Inc. (Case No. 230904627): Landlord lawsuit alleging anticipatory repudiation, breach of contract, and breach of the implied covenant of good faith and fair dealing, seeking monetary damages and attorneys fees. Recursion has filed counterclaims alleging breach of contract and fraudulent misrepresentation. Discovery is ongoing, and the company cannot estimate the range of damages for its counterclaims.

Stakeholder Impact

• Shareholders: Continued substantial net losses and accumulated deficit, coupled with a significant revenue decline, may impact investor confidence and necessitate future capital raises, potentially diluting existing shareholders.
• Employees: Headcount reductions mentioned as a driver for decreased general and administrative expenses, potentially impacting employee morale and workload.
• Collaborators (Sanofi, Merck, Roche/Genentech): Progress in pipeline programs and platform advancements are positive for collaborations. Revenue recognition from these partnerships is subject to milestone achievement and project phase completion.
• Creditors: The company's substantial cash reserves provide a buffer, but continued losses and the need for future financing could impact long-term creditworthiness.

Next Steps

• Continue dose escalation for REC-1245 to determine the recommended Phase 2 dose.
• Initiate FDA engagement to align on a potential registrational study design for REC-4881.
• Expand TUPELO study to include patients aged 18+.
• Complete IND-enabling studies for REC-7735 and REC-102, with a go/no-go decision expected in 2H26.
• Present additional Phase 1b/2 clinical data for REC-4881 in 1H27.
• Present additional Phase 1 dose escalation data for REC-1245 in 2H26.
• Present early Phase 1 safety and PK combination data for REC-617 in 1H27.
• Present early Phase 1 safety and PK monotherapy data for REC-3565 in 1H27.
• Present early Phase 1 safety and PK monotherapy data for REC-4539 in 2H27.
• Continue advancing partnered programs with Sanofi and Roche/Genentech.
• Continue implementing IT general controls and financial processes for Exscientia integration.
• Continue evaluating the design and operating effectiveness of controls impacted by new ERP and P2P system implementations.

Key Dates

Recommendation

Recursion Pharmaceuticals presents a classic high-risk, high-reward profile. The company's AI-driven platform and promising early-stage pipeline are significant positives, as demonstrated by the speed of development for REC-1245 and positive data for REC-4881. However, the substantial and persistent net losses, coupled with a significant decline in revenue and the ongoing need for capital, create considerable financial risk. The material weaknesses in internal controls also warrant caution. While the long-term potential is evident, the near-to-medium term financial sustainability and execution risk necessitate a 'hold' recommendation until revenue streams stabilize or significant progress is made towards profitability.

Keywords

Recursion Pharmaceuticals, 10-Q Filing, Drug Discovery, AI in Healthcare, Biotechnology, Clinical Stage, REC-1245, REC-4881, Recursion OS, Financial Results, SEC Filings